08.11.2018, 2738 Zeichen

Wienerberger: International producer of bricks increased revenues in the first nine months of 2018 by 6% to Euro 2,495.2 mn. Adjusted EBITDA (excluding one-off expenses and income) grew by 16% to Euro 356.4 mn. The net profit soared by 33% to Euro 125.7 mn. Given its performance during the past three quarters, Wienerberger again confirms its refined adjusted EBITDA target of Euro 460 mn to Euro 470 mn. In the medium term, Wienerberger now aims at an increased EBITDA target of approx. Euro 680 mn for 2020 (post implementation of IFRS16).
Wienerberger: weekly performance: 0.49%

Bawag: Bawag Group reached profit before tax of Euro 429 mn (+14%) for the first three quarters 2018. Net interest income increased by 5.9% to Euro 623.4 mn in the first three quarters 2018. Net fee and commission income increased by 40.9% to Euro 212.6 mn compared to the first three quarters 2017, mainly due to the acquisitions of PayLife and Südwestbank, which were closed in the fourth quarter 2017, and lower commission expenses paid to the Austrian Post. Anas Abuzaakouk, CEO of Bawag Group AG, said: "We will continue to execute on a number of operational and strategic initiatives during the remainder of 2018. Our focus remains on driving operational excellence and profitable growth, and we are confident in exceeding all of our 2018 targets."
Bawag Group: weekly performance: 3.68%

Valneva: Austrian/French vaccines company Valneva’s total revenues in the first nine months of 2018 were Euro 78.3 mn compared to Euro 76.3 mn in the first nine months of 2017. In the first nine months of 2018, Valneva realized an operating profit of Euro 0.9 mn compared toan operating profit of Euro 0.2 mn in the first nine months of 2017. EBITDA in the first nine monthsof 2018 was Euro 6.1 mn, compared to an EBITDA of Euro 12.3 mn in the first nine months of 2017. According to the company, the reduction was driven by the increased investments into Research & Development and Marketing & Distribution. For the financial year EBITDA is expected in the range of Euro 5 mn to 10 mn, revenues and grants are exprected of Euro 110 mn - Euro 120 mn, the company stated in its outlook.
Valneva: weekly performance: -4.72%

Themis Bioscience: Austrian Themis Bioscience, a biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, decided to postpone its listing on Euronext Amsterdam due to adverse market conditions, concluding that an IPO would not be in the interest of the Company or its shareholders at this time. Themis said it will continue to investigate all strategic options, including financings, for the development of its programs.

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/11/2018)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1075: ATX leichter; Telekom, VIG und Uniqa gesucht, Verbund x Nordex, Strafe für CA Immo hat ev. zu viel Signalwirkung

Bildnachweis

Aktien auf dem Radar:Amag, Polytec Group, Austriacard Holdings AG, Kapsch TrafficCom, Semperit, Rosenbauer, Uniqa, VIG, Zumtobel, Marinomed Biotech, Frequentis, Wienerberger, Mayr-Melnhof, Palfinger, FACC, Pierer Mobility, Rath AG, Agrana, BKS Bank Stamm, Oberbank AG Stamm, Österreichische Post, Verbund.

---